Cigarette smoking and parkinson’s disease

Neurology

Volumn 36, Issue 11, 1986, Pages 1490-1496

  Baron, John A ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL NERVOUS SYSTEM; CIGARETTE SMOKING; EPIDEMIOLOGY; ETIOLOGY; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

BRAIN; DOPAMINE; FEMALE; HUMAN; MALE; NICOTINE; PARKINSON DISEASE; PLANTS, TOXIC; SMOKING; SUPPORT, NON-U.S. GOV'T; TOBACCO;

EID: 0023002764     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/wnl.36.11.1490     Document Type: Article

References (122)

1. Kahn HA. The Dorn study of smoking and mortality among US. veterans: report on eight and one-half years of observation. In: Haenszel W, ed. Epidemiological approaches to the study of cancer and other chronic diseases. US. Department of Health, Education and Welfare, National Cancer Institute Monograph 19, 1966.
2. Hammond EC. Smoking in relation to the death rates of one million men and women. In: Haenszel W, ed. Epidemiological approaches to the study of cancer and other chronic diseases. US. Department of Health, Education and Welfare, National Cancer Institute Monograph 19, 1966.
3. Doll R, Peto R. Mortality in relation to smoking: 20 years’ observations on male British doctors. Br Med J 1976;25:1525–36.
4. Hirayama T. Epidemiological patterns of Parkinson’s disease based on a cohort study. Tokyo: Japan Ministry of Health and Welfare, Epidemiology of Intractable Diseases Research Committee, 1985.
5. Nefzger MD, Quadfasel FA, Karl VC. A retrospective study of smoking in Parkinson’s disease. Am J Epidemiol 1968;88:149–58.
6. Kessler II, Diamond EL. Epidemiologic studies of Parkinson’s disease. I. Smoking and Parkinson’s disease: a survey and explanatory hypothesis. Am J Epidemiol 1971;94:16–25.
7. Kessler II. Epidemiologic studies of Parkinson’s disease. III. A community-based survey. Am J Epidemiol 1972;96:242–54.
8. Ansari KA, Johnson A. Olfactory function in patients with Parkinson’s disease. J Chronic Dis 1975;28:493–7.
9. Marttila RJ, Rinne UK. Smoking and Parkinson’s disease. Acta Neurol Scand 1980;62:322–5.
10. Haack DG, Baumann RJ, McKean HE, et al. Nicotine exposure and Parkinson’s disease. Am J Epidemiol 1981;114:191–200.
11. Duvoisin RC, Eldridge R, Williams A, Nutt J, Calne D. Twin study of Parkinson disease. Neurology (NY) 1981;31:77–80.
12. Ward CD, Duvoisin RC, Ince SE, Nutt JD, Eldridge R, Calne DB. Parkinson’s disease in 65 pairs of twins and in a set of quadruplets. Neurology (Cleveland) 1983;33:815–24.
13. Godwin-Austen RB, Lee PN, Marmot MG, Stern GM. Smoking and Parkinson’s disease. J Neurol Neurosurg Psychiatry 1982;45:577–81.
14. Barbeau A, Pourcher E. New data on the genetics of Parkinson’s disease. Can J Neurol Sci 1982;9:53–60.
15. Kondo K. Epidemiological clues for the etiology of Parkinson’s disease. Adv Neurol 1984;40:345–51.
16. Kondo K. Epidemiological evaluation of the risk factors of Parkinson’s disease. Adv Neurol (in press).
17. Rajput AH. Epidemiology of Parkinson’s disease. Can J Neurol Sci 1984;11:156–9.
18. Rajput AH, Offord K, Beard CM, Kurland LT. A case-control study of smoking habits and other illnesses in patients with parkinsonism (submitted for publication).
19. Cazzato G, Capus L, Monti F, Carraro N. Abitudine al fumo e morbo di Parkinson. Riv Neurol 1985;55:79–87.
20. Duvoisin RC. Is Parkinson’s disease acquired or inherited? Can J Neurol Sci 1984;11:151–5.
21. Calne DB, Langston JW. Aetiology of Parkinson’s disease. Lancet 1983;2:1457–9.
22. Marttila RJ. Etiology of Parkinson’s disease. In: Rinne UK, Klinger M, Stamm G, eds. Parkinson’s disease: current progress, problems and management. New York: Elsevier/North Holland Biomedical Press, 1980:3–15.
23. Cote L. Basal ganglia, the extrapyramidal motor system. and diseases of transmitter metabolism. In: Kandel ER, Schwarta JH, eds. Principles of neural sciences. New York: Elsevier, 1981:347–57.
24. Hornykiewicz O. Brain neurotransmitterchanges in Parkinson’s disease. In: Marsden CD, Fahn S, eds. Neurology 2: movement and disorders. London: Butterworth Scientific, 1982:41–58.
25. US Surgeon General. Smoking and health. Washington: Department of Health, Education and Welfare, 1979.
26. Jaffe JH. Drug addiction and drug abuse. In: Gilman AG, Goodman LS, Rall TW, Murad F, eds. The pharmacological basis of therapeutics. New York: Macmillan, 1985:532–81.
27. Taylor P. Ganglionic stimulating and blocking agents. In: Gilman AG, Goodman LS, Rall TW, Murad F, eds. The pharmacological basis of therapeutics. New York: Macmillan, 1985:215–21.
28. Schmiterlow CG, Hansson E, Andersson G, et al. Distribution of nicotine in the central, nervous system. Ann NY Acad Sci 1967;142:2–14.
29. Sershen H, Lajtha A. Cerebral uptake of nicotine and of amino acids. J Neurosci Res 1979;4:85–9.
30. Waddell WJ, Marlowe C. In vivo and in vitro affinities of nicotine-14C and cotinine-14C for melanin and bronchi of mice. Fed Proc 1975;34:2790.
31. Szuts T, Olsson S, Lindquist NG, et al. Long-term fate of 14C-nicotine in the mouse: retention in the bronchi, melanin-containing tissues and urinary bladder wall. Toxicology 1978;10:207–20.
32. Izquíerdo I, Izquierdo JA. Effects of drugs on deep brain centers. Annu Rev Pharmacol 1971;11:189–208.
33. Aceto MD, Martin BR. Central actions of nicotine. Med Res Rev 1982;2:43–62.
34. Balfour DJK. The effects of nicotine on brain neurotransmitter systems. In: Balfour DJK, ed. Nicotine and the tobacco smoking habit. Oxford Pergamon Press, 1984.
35. Calne DB. Pharmacology of parkinsonism. In: Calne DB, ed. Parkinsonism: physiology, pharmacology and treatment. London: Edward Arnold Ltd., 1970.
36. Rinne UK. Brain neurotransmitter receptors in Parkinson’s disease. In: Marsden CD, Fahn S, eds. Neurology 2: movement disorders. London: Butterworth Scientific, 1982:59–74.
37. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research: principles and quantitative methods. Belmont, CA: Lifetime Learning Publications, 1982:320–75.
38. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research. Belmont, CA: Lifetime Learning Publications, 1982:220–41.
39. Kessler II. Parkinson’s disease in epidemiologic perspective. Adv Neurol 1978;19:355–84.
40. Schlesselman JJ. Case-control studies. New York: Oxford University Press, 1982:134.
41. Lang AE, Marsden CD, Obeso JA, Parkes JD. Alcohol and Parkinson disease. Ann Neurol 1982;12:254–6.
42. Koller WC. Alcohol and Parkinson disease. Letter. Ann Neurol 1983;13:467.
43. Bross IDJ. Spurious effects from an extraneous variable. J Chronic Dis 1966;19:637–47.
44. Colton T. Statistics in medicine. Boston: Little, Brown & Co., 1974:294–301.
45. Moll H. The treatment of post-encephalitic parkinsonism by nicotine. Br Med J 1926;1:1079–81.
46. Vartaininen I. Die atrophinbehandlung des folgezustandes der encephalitis epidemica. Acta Med Scand 1944;116:536–60.
47. Marshall J, Schnieden H. Effect of adrenaline, noradrenaline, atropine and nicotine on some types of human tremor. J Neurol Neurosurg Psychiatry 1966;29:214–8.
48. Westfall TC, Fleming RM, Fudger MF, Clark WG. Effect of nicotine and related substances upon amine levels in the brain. Ann NY Acad Sci 1967;142:83–99.
49. Andersson K, Fuxe K, Agnati LF. Effects of single injections of nicotine on the ascending dopamine pathways in the rat. Acta Physiol Scand 1981;112:345–7.
50. Andersson K, Fuxe K, Agnati LF, Eneroth P. Effects of acute central and peripheral administration of nicotine on ascending dopamine pathways in the male rat brain: evidence for nicotine induced increases of dopamine turnover in various telencephalic dopamine nerve terminal systems. Med Biol 1981;59:170–6.
51. Lienhart R, Lichtensteiger W, Langemann H. Response of nigral dopamine neurons to acute and prolonged morphine treatment. Arch Pharmacol 1975;286:353–69.
52. Lichtensteiger W, Felix D, Lienhart R, Hefti F. A quantitative correlation between single unit activity and fluorescence intensity of dopamine neurones in zona compacta of substantia nigra, as demonstrated under the influence of nicotine and physostigmine. Brain Res 1976;117:85–103.
53. Lichtensteiger W, Hefti F, Felix D, et al. Stimulation of nigrostriatal dopamine neurones by nicotine. Neuropharmacology 1982;21:963–8.
54. Andersson K, Fuxe K, Eneroth P, et al. Interactions of nicotine and pentobarbitone in the regulation of telencephalic and hypothalamic catecholamine levels and turnover and of adeno-hypophyseal hormone secretion in the normal male rat. Arch Pharmacol 1982;321:287–92.
55. Clarke PBS, Hommer DW, Pert A, Skirboll LR. Electrophysiological actions of nicotine on substantia nigra single units. Br J Pharmacol 1985;85:827–35.
56. Goodman FR. Effects of nicotine on distribution and release of 14C-norepinephrine and 14C-dopamine in rat brain striatum and hypothalamus slices. Neuropharmacology 1974;13:1025–32.
57. Westfall TC. Effect of nicotine and other drugs on the release of 3H-norepinephrine and 3H-dopamine from rat brain slices. Neuropharmacology 1974;13:693–700.
58. Arqueros L, Naquira D, Zunino E. Nicotine-induced release of catecholamines from rat hippocampus and striatum. Biochem Pharmacol 1978;27:2667–74.
59. Giorguieff-Chesselet MF, Kemel ML, Wandscheer D, Glowinski J. Regulation of dopamine release by presynaptic nicotinic recepton in rat striatal slices: effect of nicotine in a low concentration. Life Sci 1979;25:1257–62.
60. Marks MJ, Burch JB, Collins AC. Effects of chronic nicotine infusion on tolerance development and nicotinic receptors. J Pharmacol Exp Ther 1983;226:817–25.
61. Schwartz RD, Kellar KJ. Nicotinic cholinergic receptor binding sites in the brain: regulation in vivo. Science 1983;220:214–6.
62. Armitage AK, Hall GH, Sellers CM. Effects of nicotine on electrocortical activity and acetylcholine release from the cat cerebral cortex. Br J Pharmacol 1969;35:152–60.
63. Hall GH. Effects of nicotine and tobacco smoke on the electrical activity of the cerebral cortex and olfactory bulb. Br J Pharmacol 1970;38:271–86.
64. Bhagat B, Kramer SZ, Seifter J. The effects of nicotine and other drugs on the release of injected, ‘H-norepinephrine and on endogenous norepinephrine levels in the rat brain. Eur J Pharmacol 1967;2:234–5.
65. Hall GH, Turner DM. Effects of nicotine on the release of 3H-noradrenaline from the hypothalamus. Biochem Pharmacol 1972;21:1829–938.
66. Svensson TH, Engberg G. Effect of nicotine on single cell activity in the noradrenergic nucleus locus coeruleus. Acta Physiol Scand 1980;479(suppl):31–4.
67. Reichlin S. Neuroendocrinology. In: Wilson JD, Foster DW, eds. Textbook of endocrinology. Philadelphia: Saunders, 1985:492–562.
68. Blake CA, Sawyer CH. Nicotine blocks the suckling-induced rise. in circulating prolactin in lactating rats. Science 1972;177:619.
69. Blake CA, Norman RL, Scaramuzzi RJ, Sawyer CH. Inhibition of the proestrous surge of prolactin in the rat by nicotine. Endocrinology 1973;92:1334-8.
70. Ferry JK, McLean BK, Nikitovitch-Winer MB. Tobacco smoke inhalation delays suckling-induced prolactin release in the rat. Proc Soc Exp Biol Med 1974;147:110.
71. Terkel J, Blake CA, Hoover V, Sawyer CH. Pup survival and prolactin levels in nicotine-treated lactating rats. Proc Soc Exp Biol Med 1973;143:1131.
72. Blake CA. Stimulation of pituitary prolactin and TSH release in lactating and proestrous rats. Endocrinology 1974;94:503–8.
73. Blake CA. Parallelism and divergence in luteinizing hormone and follicle-stimulating hormone release in nicotine-treated rats. Proc Soc Exp Biol Med 1974;145:716.
74. Eneroth P, Fuxe K, Gustafsson JA, et al. The effect of nicotine on central catecholamine neurons and gonadotropin secretion. II. Inhibitory influence of nicotine on LH, FSH and prolactin secretion in the ovariectomized female rat and its relation to regional changes in dopamine and noradrenaline levels and turnover. Med Biol 1977;55:158.
75. Andersson K, Fuxe K, Eneroth P, Agnati LF. Involvement of cholinergic nicotine-like receptors as modulators of amine turnover in various types of hypothalamic dopamine and noradrenaline nerve terminal systems and of prolactin, LH, FSH and TSH secretion in the castrated male rat. Acta Physiol Scand 1982;116:41.
76. Andersson K, Fuxe K, Eneroth P, et al. Mecamylamine induced blockade of nicotine induced inhibition of gonadotropin and TSH secretion and of nicotine induced increases of catecholamine turnover in the rat hypothalamus. Acta Physiol Scand 1980;479(suppl):27.
77. Andersen AN, Ronn B, Tjonneland A, Djursing H, Schioler V. Low maternal but normal fetal prolactin levels in cigarette smoking pregnant women. Acta Obstet Gynecol Scand 1984;63:237.
78. Andersen AN, Lund-Andersen C, Larsen JF, et al. Suppressed prolactin but normal neurophysin levels in cigarette smoking breast-feeding women. Clin Endocrinol (Oxf) 1982;17:363.
79. Andersen AN, Schiøler V. Influence of breast-feeding pattern on pituitary-ovarian axis of women in an industrialized community. Am J Obstet Gynecol 1982;143:673–7.
80. Andersen AN, Semczuk M, Tabor A. Prolactin and pituitarygonadal function in cigarette smoking infertile patients. Andrologia 1984;16:391.
81. Baron JA, Bulbrook ER, Wang DY, Kwa HC. Cigarette smoking and prolactin in women. Br Med J (in press).
82. Whichelow M. Breast-feeding and smoking. Arch Dis Child 1979;54:240.
83. Sandberg H, Roman L, Zavodnick J, Kupers N. The effect of smoking on serum somatotropin, immunoreactive insulin and blood glucose levels of young adult males. J Pharmacol Exp Ther 1973;184:787–91.
84. Orsetti A, Amara F, Collard F, Mirouze J. Influence du tabac sur les hormones essentielles de la glycoregulation. Nouv Presse Med 1975;4:1571–2.
85. Cryer PE, Haymond MW, Santiago JV, Shah SD. Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hernodynamic and metabolic events. N Engl J Med 1976;295:573–7.
86. Wilkins JN, Carlson HE, Van Vunakis H, et al. Nicotine from cigarette smoking increases circulating levels of cortisol, growth hormone, and prolactin in male chronic smokers. Psychophar-macology (Berlin) 1982;78:305–8.
87. Coiro V, d’Amato L, Borciani E, et al. Nicotine from cigarette smoking enhances clonidine-induced increase of serum growth hormone concentrations in men. Br J Clin Pharmacol 1984;18:802–5.
88. Silvette H, Larson PS, Haag HB. Action of nicotine and tobaccosmoking on the adrenal medulla. Arch Intern Med 1961;107:181–97.
89. Westfall TC, Watts DT. Effect of cigarette smoke on epinephrine secretion in the dog. Proc Soc Exp Biol Med 1963;112:843–7.
90. Westfall TC, Watts DT. Catecholamine excretion in smokers and nonsmokers. J Appl Physiol 1964;19:40–2.
91. Turnbull MJ, Kelvin AS. Cigarette dependence. Letter. Br Med J 1971;31:15.
92. Hill P, Wynder EL. Smoking and cardiovascular disease. Am Heart J 1974;87:491–6.
93. Quigley ME, Sheehan KL, Wilkes MM, Yen SSC. Effects of maternal smoking on circulating catecholamine levels and fetal heart rates. Am J Obstet Gynecol 1979;133:685.
94. Siess W, Lorenz R, Roth P, Weber PC. Plasma catecholamines, platelet aggregation and associated thromboxane formation after physical exercise, smoking or norepinephrine infusion. Circulation 1982;66:44–8.
95. Houben H, Thien TH, Van‘t Laar A. Haemodynamic effects of cigarette smoking during chronic selective and non-selective beta-adrenoceptor blockade in patients with hypertension. Br J Clin Pharmacol 1981;12:67–72.
96. Baer L, Radichevich I. Cigarette smoking in hypertensive patients: blood pressure and endocrine responses. Am J Med 1985;78:564–8.
97. Westfall TC, Brase DA. Studies on the mechanism of tolerance to nicotine-induced elevations of urinary catecholamines. Biochem Pharmacol 1971;20:1627–35.
98. Holtz J, Sommer O, Bassenge E. Development of specific tolerance to nicotine infusions in dogs on chronic nicotine treatment. Klin Wochenschr 1984;62:51–7.
99. Dominiak P, Kees F, Grobecker H. Changes in peripheral and central catecholaminergic and serotoninergic neurons of rats after acute and subacute administration of nicotine. Klin Wochenschr 1984;62:76–80.
100. Artalejo AR, Garcia AG, Montiel C, Sanchez-Garcia P. A dopaminergic receptor modulates catecholamine release from the cat adrenal gland. J Physiol (Lond) 1985;362:359–68.
101. Boelsterli UA, Cruz-Orive LM, Zbinden G. Morphometric and biochemical analysis of adrenal medullary hyperplasia induced by nicotine in rats. Arch Toxicol 1984;56:113–6.
102. Bhagat B, Rana MW. Effect of chronic administration of nicotine on the concentrations of adrenal enzymes involved in the synthesis and metabolism of adrenaline. Br J Pharmacol 1971;43:250–1.
103. Patrick RL, Kirshner N. Effect of stimulation on the levels of tyrosine hydroxylase, dopamine beta-hydroxylase, and catecholamines in intact and denervated rat adrenal glands. Mol Pharmacol 1971;7:87–96.
104. Slotkin TA, Seidler FJ. Acute and chronic effects of nicotine on synthesis and storage of catecholamines in the rat adrenal medulla. Life Sci 1975;16:1613–22.
105. Seidler FJ, Slotkin TA. Effects of chronic nicotine administration on the denervated rat adrenal medulla. Br J Pharmacol 1976;56:201–7.
106. Otten U, Thoenen H. Mechanisms of tyrosine hydroxylase and dopamine beta-hydroxylase induction in organ cultures of rat sympathetic ganglia by potassium depolarization and cholinomimetics. Arch Pharmacol 1976;292:153–9.
107. Rosenthal RN, Slotkin TA. Development of nicotinic responses in the rat adrenal medulla and long-term effects of neonatal nicotine administration. Br J Pharmacol 1977;60:59–64.
108. Hanbauer I, Costa E. Induction of tyrosine hydroxylase in the superior cervical ganglia of rats: opposite influence of muscarinic and nicotinic receptor agonists. Neuropharmacol 1976:1585–90.
109. Lewander T, Joh TH, Reis DJ. Tyrosine hydroxylase: delayed activation in central noradrenergic neurons and induction in adrenal medulla elicited by stimulation of central cholinergic receptors. J Pharmacol Exp Ther 1977;200:523–34.
110. Ip NY, Perlman RL, Zigmond RE. Both nicotinic and muscarinic agonists acutely increase tyrosine 3-monoxygenase activity in the superior cervical ganglion. J Pharmacol Exp Ther 1982;223:280–3.
111. Naquira D, Zunino E, Arqueros L, Viveros OH. Chronic effects of nicotine on catecholamine synthesizing enzymes in rats. Eur J Pharmacol 1978;47:227–9.
112. Lewin R. Brain enzyme is the target of drug toxin. Science 1984;225:1460–2.
113. Yamamoto I, Nagai K, Inoki R. The contents of dopa and catecholamines in several rat tissues and nicotine-induced convulsions. Jpn J Pharmacol 1966;16:295–305.
114. Bhagat B, Rana MW. Effect of chronic administration of nicotine on the concentrations of adrenal enzymes involved in the synthesis and metabolism of adrenaline. Br J Pharmacol 1971;43:250–1.
115. Essman WB. Serotonin and monoamine oxidase in mourn skin: effects of cigarette smoke exposure. J Med 1977;8:95–101.
116. Sarantos-Laska C, Majewski H, McCulloch MW, Rand MJ. Mechanism of noradrenaline release from rabbit atria induced by nicotinic agonists. Arch Int Pharmacodyn Ther 1980;247:294–305.
117. Oreland L, Fowler CJ, Schalling D. Low platelet monoamine oxidase activity in cigarette smokers. Life Sci 1981;29:2511–8.
118. Propping P, Rey E-R, Friedl W, Beckmann H. Platelet monoamine oxidase in healthy subjects: the “biochemical high-risk paradigm” revisited. Arch Psychiatr Nervenkr 1981;230:209–19.
119. Coursey RD, Buchsbaum MS, Murphy DL. Two-year follow-up of subjects and their families defined as at risk for psychopathology on the basis of platelet MA0 activities: 2-year follow-up of low platelet MAO. Neuropsychobiology 1982;8:51–6.
120. Glover V, Littlewood JY, Sandler M, et al. Platelet monoamine oxidase activity and headache: relationship to personality and smoking. Psychopharmacol Bull 1984;20:536–8.
121. Snyder SH, D’Amato RJ. MPTP: a neurotoxin relevant to the pathophysiology of Parkinson’s disease. Neurology 1986;36:250–8.
122. Morley BJ. The properties of brain nicotine receptors. In: Balfour DJK, ed. Nicotine and the tobacco smoking habit. New York: Pergamon Press, 1984:31–44.